17 July 2020
The first stage of testing of a Russian vaccine against the novel coronavirus developed at the N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology went successfully, and the second stage will conclude on August 3, 2020, head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev said during an online press conference on Thursday.
Yesterday, the first stage of clinical testing of a Russian vaccine ended <…>, it went very successfully. The second stage of testing of the Russian vaccine will conclude on august 3,” he said.
According to the RDIF, Russia will produce about 30 mln doses of COVID-19 vaccine by the end of 2020, with the required amount of 50 mln doses. The full vaccination of Russians may be complete by early 2021.
Globally, about 200 mln doses of vaccines are expected to be produced by the end of 2020. “According to predictions, next year, about 3 bln vaccines based on the adenovirus vector will be produced: not only the Russian vaccine, but the Oxford University vaccine and the Chinese vaccine as well,” Dmitriev added.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024